Oncoclínicas&Co and Al Faisaliah Group Join Forces to Revolutionize Cancer Care in Saudi Arabia I n a groundbreaking development poised to transform cancer treatment in the Middle East, Latin America’s premier oncology group, Oncoclínicas&Co, has announced a strategic joint venture with Saudi Arabia’s Al Faisaliah Group. This partnership aims to introduce state of-the-art cancer treatment facilities in the Kingdom, beginning with a f lagship center in Riyadh. A Milestone in Healthcare Cooperation The collaboration between Oncoclínicas&Co and Al Faisaliah Group marks a significant milestone in international healthcare cooperation. By leveraging Oncoclínicas&Co’s extensive oncology leader in oncology services across Latin America. Comprehensive Care Model Oncoclínicas&Co is distinguished by its holistic approach to cancer treatment, emphasizing the complete patient journey. Their model integrates operational efficiency, personalized care, and high specialization. With a team of 2,700 specialist physicians across 145 units in 39 Brazilian cities, Oncoclínicas&Co has proven its capability to deliver high quality, accessible cancer care on a large scale. The organization has developed The collaboration between Oncoclínicas&Co and Al Faisaliah Group marks a significant milestone in international healthcare cooperation expertise alongside Al Faisaliah Group’s profound understanding of the Saudi market, the joint venture is set to address the growing demand for accessible oncological services in Saudi Arabia and the surrounding region. Dr. Bruno Ferrari, founder of Oncoclínicas&Co, identified the potential for enhancing cancer care during an observership at the renowned M.D. Anderson Cancer Center in Houston. This pivotal experience led him to establish Oncoclínicas&Co in Brazil 14 years ago, which has since evolved into a standardized protocols aligned with best-in-class international pathways and the latest scientific evidence. The joint venture will provide a broad spectrum of services, including diagnostics, infusional treatments such as chemotherapy and immunotherapy, and radiotherapy. Vision for the Future HRH Mohammed K.A. Al Faisal, President of Al Faisaliah Group and the future Chairman of the joint venture, expressed his enthusiasm about the potential impact of this partnership: “We’re joining forces to improve cancer care. Our aim is to become the top private cancer treatment center for a region of over 300 million people. We’ll offer advanced treatments and expert care to save lives and raise the bar in cancer treatment.” The initial phase of the project involves establishing a cutting-edge outpatient cancer care center in Riyadh. This facility will feature the latest medical technologies and will be staffed by leading oncologists from within the Kingdom. Encompassing 9,000 square meters, www.medgatetodayglobal.com the Riyadh facility is expected to include 70 chemotherapy boxes and two radiotherapy bunkers. This initial center will serve as a prototype for future expansion, with plans to create a network of outpatient clinics throughout Saudi Arabia. Investment and Growth Potential Oncoclínicas&Co plans to invest between $10 20 million over the next three years, with total investments anticipated to reach between $20-40 million. The Brazilian firm will hold a 51% share in the joint venture, while Al Faisaliah Group will retain the remaining 49%. Dr. Ferrari underscored the significance of this www.medgatetodayglobal.com expansion: “We are thrilled to expand our premier oncology treatment services to KSA and the GCC nations. Our innovative service model will provide cancer patients with greater access to best-in-class care, and our dynamic business model will offer our shareholders and partners a strong foothold for growth in the region.” The partnership between Oncoclínicas&Co and Al Faisaliah Group is expected to create a substantial impact on the Saudi Arabian healthcare landscape Impact on Saudi Arabia’s Healthcare Sector The partnership between Oncoclínicas&Co and Al Faisaliah Group is expected to create a substantial impact on the Saudi Arabian healthcare landscape. With an estimated oncology market of $3 billion in Saudi Arabia projected for 2024, according to the World Health Organization and Saudi Census, the potential for growth and improved patient outcomes is immense. As this collaboration unfolds, it promises to set a new standard for cancer care in the region, ultimately benefiting millions of patients in need of advanced oncological services